

Editorial Retraction: A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus

Hyun-Min Yoon^{1*}, The Editorial Board of Journal of Pharmacopuncture²

¹ Editor-in-Chief of Journal of Pharmacopuncture, Department of Acupuncture & Moxibustion, Dong-Eui University College of Oriental Medicine, Busan, Korea

² Korean Pharmacopuncture Institute, Seoul, Korea

The Editorial Office of Journal of Pharmacopuncture (JoP) received a report which is related to plagiarism issue by Leslie Lansman, the Global Permission Manager of SpringerNature. Accordingly, we began the inspection and found several plagiarized figures including Nature's notifying.

Table 1 The information of examined article

Title	A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus
Authors	Mamo Gizaw ¹ , Pandi Anandakumar ¹ (Corresponding author), Tolessa Debela ²
Institutions	¹ Biochemistry Unit, Department of Biomedical Sciences, College of Health Sciences, Arsi University, Asella, Ethiopia ² Physiology Unit, Department of Biomedical Sciences, College of Health Sciences, Arsi University, Asella, Ethiopia
Publication	Journal of Pharmacopuncture 2017;20[4]:235-242
DOI	https://doi.org/10.3831/KPI.2017.20.029

Table 2 Discovered particulars of plagiarism

Plagiarized figure in the article	Original source
Figure 1	Figure 1.6 of "Investigating a potential role for irisin as a biomarker in the early detection of Alzheimer's disease" [1]
Figure 2	Figure 2 of "Weight Loss: A New Star is Irisin" [2]

Received: Mar 26, 2020 Accepted: Mar 26, 2020

Figure 4	Figure 4 of "Physiology and role of irisin in glucose homeostasis" [3]
Figure 5	Figure 2 of "Physiology and role of irisin in glucose homeostasis" [3]
Figure 6	Figure 8 of "FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity" [4]
Figure 7	A figure of "Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes" [5]
Figure 8	Figure 1 of "The p38-PGC-1 α -irisin/betatrophin axis" [6]

The corresponding author had explained that "This article is not a research but a review which is collected in already existing research and has appropriate references."

The authors of this article committed serious research misconduct. The editors of JoP are convinced an immediate, absolute retraction is needed.

Therefore, we retract this manuscript. Also, we inform researchers and medicine community that the contents and results of this paper is invalid.

We, the Editorial Board of Journal of Pharmacopuncture, seriously take this research ethics violation. We sincerely apologize to the reviewers, editors who devoted their time and endeavor to evaluate the article and medicine community.

References

1. Sabine Maria Bird. Investigating a potential role for irisin as a biomarker in the early detection of Alzheimer's disease [dissertation]. The University of Western Australia; 2018. 402p. DOI:10.4225/23/5b2af9560e3f7
2. Thomas G. Brock. Weight Loss: A New Star is Irisin [Internet]. Cayman Chemical; [cited 2020 March 26]. Available from: <https://www.caymanchem.com/news/weight-loss-and-irisin/>.
3. Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, et al. Physiology and role of irisin in glucose homeostasis. *Nature*. 2017;13:324-37. DOI:10.1038/nrendo.2016.221
4. Xiong XQ, Chen D, Sun HJ, Ding L, Wang JJ, Chen Q, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. *BBA Molecular Basis of Disease*. 2015;1852(9):1867-75. DOI:10.1016/j.bbadis.2015.06.017
5. Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. *Clinical Science*. 2015;129(10):839-50. DOI:10.1042/CS20150009
6. Sanchis-Gomar F, Perez-Quilis C. The p38-PGC-1 α -irisin-betatrophin axis. *Adipocyte*. 2013;3(1):67-8. DOI:10.4161/adip.27370